If you have been reading about pituitary axis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
== Metrology == A number of reference materials are available for silver nanoparticles. NIST RM 8017 contains 75 nm silver nanoparticles embedded in a cake of the polymer polyvinylpyrrolidone to stabilize them against oxidation for a long shelf life. They have reference values for mean particle size using dynamic light scattering, ultra-small-angle X-ray scattering, atomic force microscopy, and transmission electron microscopy; and size distribution reference values for the latter two methods. The BAM-N001 certified reference material contains silver nanoparticles with a specified size distribution with a number-weighted median size of 12.6 nm measured by small-angle X-ray scattering and transmission electron microscopy.
Willie Limond, 45, Scottish boxer and footballer (Albion Rovers), complications from a seizure. 18 April – Dave Moyes, 68, Scottish footballer (Berwick Rangers, Meadowbank Thistle, Dunfermline Athletic). 23 April – Fergie MacDonald, 86, Scottish accordionist. 28 April – Brian McCardie, 59, Scottish actor (Rob Roy, Speed 2: Cruise Control, Ellie Parker) and writer. 29 April – Christian, 80, Scottish singer and entertainer. 3 May – Jim Rodger, 90, Scottish footballer (St Mirren, Rangers, Queen of the South). 14 May – Gudrun Ure, 98, Scottish actress (Super Gran, The Million Pound Note, The Crow Road). 20 May – Gerry Collins, 69, Scottish football player (Ayr United, Hamilton Academical, Partick Thistle) and manager. 22 May – David Wilkie, 70, Scottish swimmer, Olympic champion (1976), world champion (1973, 1975), cancer. 24 May – Stuart Borrowman, 71, Scottish politician. 29 May – John Burnside, 69, Scottish writer and poet. 5 June – David Scott, 83, Scottish journalist and broadcaster (Scottish Daily Express, BBC Scotland, STV). (death announced on this date) 18 June – Billy Abercromby, 65, Scottish footballer (St Mirren, Partick Thistle, Dunfermline Athletic). (death announced on this date) 26 June – Pat Heywood, 92, actress (Lucky Feller, Wuthering Heights, Inspector Morse, Root Into Europe) 27 June – Donald Scott, 96, Scottish rugby union player (Langholm, South of Scotland District, national team). 28 July – John Anderson, 92, Scottish television personality (Gladiators). 4 August – Jim Doherty, 65, Scottish footballer (Kilmarnock, Clyde, Queen of the South).
Olaf is a humorless villain in the book. He's not amusing like Carrey at all. To which I would counter: If you can't let Carrey be Carrey, put someone boring and less expensive in the role. In his various disguises he's rubbery, inventive and improvisationally inspired. I particularly liked his passing imitation of a dinosaur. That same year, Carrey was inducted into the Canadian Walk of Fame. In 2005, Carrey starred in the remake of Fun with Dick and Jane with Téa Leoni, which grossed $200 million with a profit of $100 million. Carrey was initially cast to provide the voice of RJ for the DreamWorks Animation film Over the Hedge, but he ultimately quit the project because he was uncomfortable with not having full control over his character's physical and facial movements.
Sources: en.wikipedia.org
=== Bombing of Laos === In February 1970, several senators led by J. William Fulbright and Stu Symington first learned that the United States had been bombing Laos since December 1964, which led to complaints in Congress about the "secret war" in Laos. Nixon reluctantly decided to admit to the "secret war", and directed Kissinger to issue the necessary statement to the media. Kissinger's statement admitted to the bombing of Laos, but also claimed: "No American stationed in Laos has ever been killed in ground combat operations". Two days later, it emerged that a U.S. Army captain had been killed while fighting in Laos and subsequently the Pentagon admitted that in the period February 1969-February 1970 a total of 27 Americans had been killed in Laos. Kissinger claimed that he had not lied, maintaining that all Americans killed in Laos were in "hot pursuit" when chasing the enemy from South Vietnam into Laos, but this argument made no impression. Nixon stated: "No one cares about B-52 strikes in Laos, but people worry about our boys out there". Nixon refused to see Kissinger for the next week, saying that his statement about Laos had caused him to drop 11 points in the public opinion polls.
Manual tests can be used to independently confirm abnormal results. Approximately 10–25% of samples require a manual blood smear review, in which the blood is stained and viewed under a microscope to verify that the analyzer results are consistent with the appearance of the cells and to look for abnormalities. The hematocrit can be determined manually by centrifuging the sample and measuring the proportion of red blood cells, and in laboratories without access to automated instruments, blood cells are counted under the microscope using a hemocytometer. In 1852, Karl Vierordt published the first procedure for performing a blood count, which involved spreading a known volume of blood on a microscope slide and counting every cell. The invention of the hemocytometer in 1874 by Louis-Charles Malassez simplified the microscopic analysis of blood cells, and in the late 19th century, Paul Ehrlich and Dmitri Leonidovich Romanowsky developed techniques for staining white and red blood cells that are still used to examine blood smears. Automated methods for measuring hemoglobin were developed in the 1920s, and Maxwell Wintrobe introduced the Wintrobe hematocrit method in 1929, which in turn allowed him to define the red blood cell indices. A landmark in the automation of blood cell counts was the Coulter principle, which was patented by Wallace H. Coulter in 1953. The Coulter principle uses electrical impedance measurements to count blood cells and determine their sizes; it is a technology that remains in use in many automated analyzers.
== Medical use == The main advantage of this drug is that it has a fast onset of action when taken orally, and has a high bioavailability which means that oral dosing produces almost as much effect as injection. It also has a relatively low tendency to cause constipation which is a common problem with opioid analgesics used for cancer pain relief, and tolerance to the analgesic effects develops relatively slowly compared to most other short-acting opioids.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.